Advances in the Treatment of Lupus Nephritis
- 1 February 2001
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 52 (1), 63-78
- https://doi.org/10.1146/annurev.med.52.1.63
Abstract
▪ Abstract Systemic lupus erythematosus (SLE) is an autoimmune disease that leads to the formation and deposition of immune complexes throughout the body, which are pathogenic for the disease. Different forms of glomerulonephritis can occur in patients with SLE and can contribute significantly to the associated morbidity and, ultimately, mortality from the disease. Over the past two decades, there have been significant strides in our understanding of the disease and in treatments that attempt to control the formation and deposition of anti-DNA auto-antibodies and immune complexes, as well as the subsequent inflammatory cascade mediated through various cellular and humoral pathways leading to progressive renal damage and end-stage renal disease. In this chapter, we review the current understanding of the pathogenesis and treatment of lupus nephritis in its various stages and discuss the experimental and human data regarding some of the potential newer forms of therapy. We discuss data regarding the use of steroids, azathioprine, cyclophosphamide, cyclosporine A, mycophenolate mofetil, gammaglobulin, plasmapheresis, LJP 394, flaxseed oil, bindarit, anti-CD40 ligand, and CTLA4Ig.Keywords
This publication has 51 references indexed in Scilit:
- Cyclosporine Treatment of Glomerular DiseasesAnnual Review of Medicine, 1999
- Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamideAmerican Journal of Kidney Diseases, 1998
- Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritisKidney International, 1996
- Treatment‐free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamideArthritis & Rheumatism, 1994
- Human glomerular mesangial cells express CD16 and may be stimulated via this receptorKidney International, 1994
- Treatment of Murine Lupus with CTLA4IgScience, 1994
- Increased urinary excretion of platelet activating factor in mice with lupus nephritisLife Sciences, 1991
- Improvement of Histological and Immunological Change in Steroid and Immunosuppressive Drug-Resistant Lupus nephritis by High-Dose Intravenous Gamma GlobulinNephron, 1989
- Effects of cyclosporine in severe systemic lupus erythematosusThe Journal of Pediatrics, 1987
- Therapy of Lupus NephritisNew England Journal of Medicine, 1986